The anti-parasitic drug Ivermectin showed significant results in clinical trials after 98 percent of studies conducted to gauge its effectiveness against Covid-19 exhibited positive effects.
In its latest bulletin dated 6 May, the ivmmeta.com said 98.1 percent or 52 out of 53 studies done worldwide resulted in 100 percent positive effects.
Out of the numbers, 19 out of 19 studies showed positive effects in early treatment; 19 out of 20 studies record positive effects in early treatment and 14 out of 14 studies reported positive effects.
The probability that Ivermectin will be ineffective as a treatment after generating positive results in the said studies, according to the website, is estimated to be 1 in 167 trillion.
Early treatment refers to treatment done immediately or soon after symptoms of Covid-19 appear, late treatment refers to more delayed treatment while prophylaxis refers to regularly taking medication to present becoming sick, in order to prevent or minimize infection.
For mortality and severe symptoms, the results showed 80 percent to 96 percent lower mortality for patients who used it as early treatment and prophylaxis.
Statistically significant improvements are seen for mortality, ventilation, hospitalization, cases, and viral clearance.
In the Philippines, political figures, and medical groups such as the Concerned Doctors and Citizens of the Philippines are pushing for the use of Ivermectin in the country.
The group of doctors claimed 22 percent of the world is already using the medication to fight Covid-19 including India, South Africa, and many Latin American countries.
The Food and Drug Administration (FDA) has approved it for compassionate use in five hospitals in the country but repeatedly warned the public against using it due to the lack of data from clinical trials approving its claims.
To test its efficacy, the Department of Health on Friday announced it allocated P22 million for an 8-month clinical trial that will determine its effect on coronavirus. The actual study will be managed by the Department of Science and Technology.